Johnson & Johnson (NYSE:JNJ) Shares Purchased by Ullmann Wealth Partners Group LLC

Ullmann Wealth Partners Group LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 190.4% during the 1st quarter, Holdings Channel reports. The fund owned 15,314 shares of the company’s stock after acquiring an additional 10,041 shares during the quarter. Ullmann Wealth Partners Group LLC’s holdings in Johnson & Johnson were worth $2,540,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in the business. WealthTrak Capital Management LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter valued at $26,000. Mountain Hill Investment Partners Corp. acquired a new position in shares of Johnson & Johnson during the 4th quarter valued at $29,000. Bay Harbor Wealth Management LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter valued at $32,000. Conquis Financial LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter valued at $33,000. Finally, Bernard Wealth Management Corp. acquired a new position in shares of Johnson & Johnson during the 4th quarter valued at $36,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on JNJ. Morgan Stanley lifted their price target on Johnson & Johnson from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 16th. Leerink Partners cut Johnson & Johnson from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Sanford C. Bernstein restated a “market perform” rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. The Goldman Sachs Group upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $157.00 to $172.00 in a report on Wednesday, April 9th. Finally, Raymond James decreased their target price on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a report on Monday, April 14th. Eleven analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $170.88.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $153.50 on Friday. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $369.32 billion, a price-to-earnings ratio of 23.08, a P/E/G ratio of 2.56 and a beta of 0.42. The stock’s fifty day simple moving average is $153.56 and its 200-day simple moving average is $153.67.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. On average, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be given a dividend of $1.30 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.39%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.